Nebulizer – In vitro Bioequivalence testing requirements: A review

  • Shubham Prajapati Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.
  • Sanjay Saha Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.
  • B Shambulingappa Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.
  • Dilip Kumar Ch. Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.
  • Bikash Sahoo Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Abstract

Generic Nebulized aerosol is often perceived as inferior to their branded counterparts; however, they are safe and effective if they can meet the regulatory requirements. International regulatory agencies have developed recommendations and guidance for bioequivalence approaches of orally inhaled drug products (OIDPs) for local action. The objective of this article is to discuss the approaches can be used for to show bioequivalence requirement for Food and Drug Administration (FDA) in the United States of America (USA) with reference product. This review endorsed that inhalation solutions and suspensions undertaken to determine the drug substance delivery rate, total drug substance delivered and Aerodynamic assessment of nebulized aerosols [aerodynamic particle size distribution (APSD)/droplet size distribution (DSD)].These are the most important parameters in characterization, evaluation and bioequivalence studies of nebulizers. These devices operate continuously; once loaded and require little or no co-ordination on the part of user they proved that these devices suitable for weak, pediatric or geriatric patients. The regulatory agencies declared that; there is no specific requirements testing in case of nebulizers like Metered dose inhalers (MDI) and Dry powder inhalers (DPIs). In United States of America (USA) regulation falls under the auspices of centre for devices and radiological health (CDRH), and new devices require 510(k) premarket notification. This review outlines all the bioequivalence test parameter.


 

Keywords: In-Vitro equivalence, APSD, Unit Dose Content, delivered dose, Morphologically-Directed Raman Spectroscopy (MDRS)

Downloads

Download data is not yet available.

Author Biographies

Shubham Prajapati, Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Sanjay Saha, Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

B Shambulingappa, Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Dilip Kumar Ch., Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Bikash Sahoo, Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

Orbicular Pharmaceutical Technologies Pvt Ltd, R&D Center, Plot No: 53, ALEAP Industrial Estate, Behind Pragati Nagar Colony, Kukatpally, Hyderabad – Telangana, India.

References

1. Byron Pr. United States Pharmacopeia recommendations for the testing of inhalers. Journal of aerosol medicine. 1998 ;11:S-11.
2. Faarc Dr. Nebulizers: principles and performance. Respiratory care. 2000; 45(6):609.
3. Newman SP. Nebuliser therapy: scientific and technical aspects. Draco; 1989.
4. Dennis J, Berg E, Sandell D, Kreher C, Karlssin M, Lamb P. European Pharmaceutical Aerosol Group (EPAG) nebulizer sub-team: assessment of proposed European Pharmacopoeial (Ph. Eur.) monograph Preparations for Nebulization. J Aerosol Med. 2007; 20: 40.
5. Hess D. Aerosol Delivery Devices in the Treatment of Asthma; Respiratory Care, 2008; 53(6):699-725.
6. Hou S, Wu J, Li X, Shu H. Practical, regulatory and clinical considerations for development of inhalation drug products. Asian journal of pharmaceutical sciences. 2015; 10(6):490-500.
7. Lee, Sau L., Bhawana Saluja, Alfredo García-Arieta, Gustavo Mendes Lima Santos, Ying Li, Sarah Lu, Shuguang Hou et al. "Regulatory considerations for approval of generic inhalation drug products in the US, EU, Brazil, China, and India." 2015:1285-1304.
8. Egusa, Kenji, Fumiaki Okazaki, Joerg Schiewe, Ulrike Werthmann, and Markus Wolkenhauer. "Identification of Polymorphic Forms of Active Pharmaceutical Ingredient in Low-Concentration Dry Powder Formulations by Synchrotron X-Ray Powder Diffraction." Drugs in R&D 17, 2017; (3):413-418.
9. Patton, J. S., & Byron, P. R. Inhaling medicines: delivering drugs to the body through the lungs. Nature Reviews Drug Discovery, 2007; 6(1):67-74.
10. Selby, Matthew D., Pieter D. de Koning, and Dannielle F. Roberts. "A perspective on synthetic and solid-form enablement of inhalation candidates." Future medicinal chemistry. 201; (13):1679-1701.
11. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_Inhalation_Sus_2092
12. Berlinski A, Hayden JB. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. Journal of aerosol medicine and pulmonary drug delivery. 2010; 23(6):397-404.
13. Dennis J, Berg E, Sandell D, Ali A, Lamb P, Tservistas M, Karlsson M, Mitchell J. Cooling the NGI-an approach to size a nebulised aerosol more accurately. Pharm Europa scientific notes. 2008; (1):27-30.
14. Hiller C, Mazumdar M, Wilson D, Bone R. Aerodynamic size distribution of metered-dose bronchodilator aerosols. American Review of Respiratory Disease. 1978; 118(2):311-7.
15. Peters TM, Chein H, Lundgren DA, Keady PB. Comparison and combination of aerosol size distributions measured with a low-pressure impactor, differential mobility particle sizer, electrical aerosol analyser, and aerodynamic particle sizer. Aerosol Science and Technology. 1993; 19(3):396-405.
16. Fromen CA, Shen TW, Larus AE, Mack P, Maynor BW, Luft JC, DeSimone JM. Synthesis and characterization of monodisperse uniformly shaped respirable aerosols. AIChE Journal. 2013; 59(9):3184-94.
17. Marple VA, Olson BA, Santhanakrishan K, Roberts DL, Mitchell JP, and Hudson-Curtis BL: Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med. 2004; (17):335–343.
18. http://dissolutiontech.com/issues/201802/inews-copley02.php
19. Copley M. Improving inhaled product testing: methods for obtaining better in vitro-in vivo relationships. Pharmaceutical Technology. 2013; 2(2):37.
20. https://www.copleyscientific.com/files/ww/news/.
21. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective, AAPS J. 2019; 7;21(2):14
22. https://www.accessdata.fda.gov/drugsatfda_docs/anda/2009.
23. https://www.malvernpanalytical.com/en/products/product-range/morphologi-range/morphologi-g3-id
24. http://www.pharmtech.com/morphologically-directed-raman-spectroscopy-uncovering-good-bad-and-ugly-drug-formulations.Song X, Hu J, Zhan S, Zhang R, Tan W. Effects of temperature and humidity on laser diffraction measurements to jet nebulizer and comparison with NGI. AAPS Pharm SciTech. 2016; 17(2):380-8.
25. USP<1601>Page no. 7875, 2018, USP 41.
26. JayeshKumar, S.M., Yashvi, P., Bhimani, B., Patel, G., Patel, J. and Patel, U. Nebulization Therapy for Lung Cancer. Research Journal of Pharmacy and Technology, 2019; 12(2):920-934.
27. Mitchell JP, Nagel MW, Nichols S, Nerbrink O. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. Journal of aerosol medicine. 2006; 19(4):409-33.
28. https://www.mspcorp.com/pharmaceutical/ngi-cooler.
29. Vecellio None L, Grimbert D, Becquemin MH, Boissinot E, Le Pape A, Lemarié E, Diot P. Validation of laser diffraction method as a substitute for cascade impaction in the European Project for a Nebulizer Standard. Journal of aerosol medicine. 2001; 14(1):107-14.
30. Bouwman AM, Heijstra MP, Schaefer NC, Duiverman EJ, Lesouëf PN, Devadason SG. Improved efficiency of budesonide nebulization using surface-active agents. Drug delivery. 2006; 13(5):357-63.
31. Pham S, Ferguson GT, Kerwin E, Goodin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. Journal of aerosol medicine and pulmonary drug delivery. 2018 ;31(3):162-9.
32. https://www.malvernpanalytical.com/en/products/product-range/spraytec.
Statistics
85 Views | 108 Downloads
How to Cite
Prajapati, S., Saha, S., Shambulingappa, B., Ch., D., & Sahoo, B. (&nbsp;). Nebulizer – In vitro Bioequivalence testing requirements: A review. Asian Journal of Pharmaceutical Research and Development, 8(1), 78-81. https://doi.org/https://doi.org/10.22270/ajprd.v8i1.647